Hofnung et al., 1992 - Google Patents
Bacterial Vectors to Target and/or Purify PolypeptidesHofnung et al., 1992
- Document ID
- 4475744769956632130
- Author
- Hofnung M
- Charbit A
- Clément J
- Leclerc C
- Martineau P
- Muir S
- O’Callaghan D
- Popescu O
- Szmelcman S
- Publication year
- Publication venue
- Targeting of Drugs 3: The Challenge of Peptides and Proteins
External Links
Snippet
The construction of recombinant proteins by genetic engineering has opened new avenues in basic research (studies on protein organization, protein folding, immunogenicity of proteins, etc) and in the development of applications (vaccines, diagnosis, targeting of …
- 229920001184 polypeptide 0 title abstract description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Löwenadler et al. | A gene fusion system for generating antibodies against short peptides | |
| AU732809B2 (en) | Compositions and methods for treating viral infections | |
| ES2336393T3 (en) | ANTIGENIC COMPLEX THAT INCLUDES AN IMMESTIMULATOR, CD4, AND A CHEMIOKIN RECEPTOR DOMAIN FOR HIV TREATMENT AND IMMUNE DISORDERS. | |
| Charbit et al. | Permissive sites and topology of an outer membrane protein with a reporter epitope | |
| US5470720A (en) | HIV antibody assays comprising p24-gp41 chimeric antigens | |
| Carlson et al. | Antibody assisted protein refolding | |
| JPH05502880A (en) | Hybrid molecule with a translocation region and a cell binding region | |
| JPS61500662A (en) | Feline leukemia virus vaccine | |
| RU2763001C1 (en) | Single-domain antibody and its modifications that specifically bind to rbds protein of sars-cov-2 virus, and method for their use for therapy and emergency prevention of diseases caused by sars- cov-2 virus | |
| Nestorowicz et al. | Antibodies elicited by influenza virus hemagglutinin fail to bind to synthetic peptides representing putative antigenic sites | |
| EP0306219A2 (en) | Novel HIV proteins and peptides useful in the diagnosis, prophylaxis or therapy of AIDS | |
| JPH05505616A (en) | Purified gp120 composition retaining native conformation | |
| Jemmerson et al. | Affinity consideration in the design of synthetic vaccines intended to elicit antibodies | |
| JP4307838B2 (en) | Peptide showing affinity for GP120 viral protein and use thereof | |
| Novella et al. | Use of substituted and tandem‐repeated peptides to probe the relevance of the highly conserved RGD tripeptide in the immune response against foot‐and‐mouth disease virus | |
| US6770631B1 (en) | Non-identical genes and their application in improved molecular adjuvants | |
| JP2004501645A (en) | Transport peptide and its analogs in C-terminal Erns peptide | |
| US6080846A (en) | Composition containing a B epitope of the envelope glycoprotein of a retrovirus and a T epitope of another distinct protein of this retrovirus | |
| Hofnung et al. | Bacterial Vectors to Target and/or Purify Polypeptides | |
| Dunn et al. | Fine mapping of the binding sites of monoclonal antibodies raised against the Pk tag | |
| Gupta et al. | Recombinant fusion proteins for haemagglutination-based rapid detection of antibodies to HIV in whole blood | |
| JPH03504729A (en) | A fusion CD4 polypeptide produced by the fusion of a substance with affinity for maltose (MalE) and a CD4 protein fragment with neutralizing properties against the HIV virus. | |
| Leclerc et al. | Immunogenicity of viral B-and T-cell epitopes expressed in recombinant bacterial proteins | |
| Kolli et al. | A synthetic dengue virus antigen elicits enhanced antibody titers when linked to, but not mixed with, Mycobacterium tuberculosis HSP70 domain II | |
| Martineau et al. | M. Hofnung, A. Charbit, J.-M. Clément, C. Leclerc |